Another study has shown that the detection of promoter methylation of MCAM, ERα, and ERβ genes in serum ctDNA could be utilized as a combined biomarker for the early detection of prostate cancer, with a sensitivity and specificity almost equal to and better than serum PSA, respectively [46]. This evidence concerns the gene ESR2 and Familial prostate cancer.